Autologous dendritic cells combined with cytokine-induced killer cells in the treatment of advanced non-small-cell lung carcinoma / 解放军医学杂志

Objective To evaluate the clinical efficacy and safety of dendritic cell (DC) combined with cytokine induced killer cell (CIK) in treatment of advanced non-small-cell lung carcinoma (NSCLC).Methods Peripheral blood mononuclear cells (PBMCs) were collected from 39 patients with advanced NSCLC,who were admitted to Affiliated Hospital of Academy of Military Medical Sciences,and cultured in vitro to produce DCs and CIK cells which,after phenotypic characterization by flow cytometry,were then returned to the patients.DCs were given subcutaneously on day 7,9,11 and 13 and CIK cells were given intravenously on day 11 and 13.The clinical efficacy and safety were analyzed before and after DCs-CIK cells treatment.Results Following up displayed that,in 39 patients with advanced NSCLC and eligible for evaluation,the objective response rate (ORR) was 30.8％ including 2 cases of completed response (CR) and 10 cases of partial response (PR),the disease control rate (DCR) was 69.2％.No significant difference existed pre-and post-treatment on the proportion of T cell subsets including CD3+CD4+CD8ˉ,CD3+CD4ˉ CD8+,CD3+CD19ˉ,CD3ˉCD 19+,CD3 CD16+CD56+,CD3+CD16+D56+,CD3+HLA-DRˉ,CD3+HLA-DR+ and CD3+CD28+CD8+ (P＞0.05),while obvious changes were found in Th1,Th2 and CD3+CD4+CD25+ T cells (Treg cells) (P＜0.05).No serious adverse events were observed.Conclusion Combined DCs-CIK cells immunotherapy provides a safe and effective treatment for patients with advanced NSCLC,improves the quality of life and relieves the probability of metastasis and recurrence.

Key Preparation Technique and Clinical Application of Frozen Platelets / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To explore the key technique for preparation of the frozen platelet and efficacy of its clinical application.</p><p><b>METHODS</b>The influences of the donators' peripheral platelet count, starting time of freeze, injection rate and evenness of the freeze-protective agent, storage mode, re-melting temperature and the capacity of water-bath etc. on the quality of the frozen platelets were analyzed retrospectively in 3 257 samples of frozen platelets before platelet pheresis. Then, the platelet counts were examined in 150 cases transfused with frozen platelets at the time-points of 1, 24, 48 and 72 hrs after transfusion, 90 cases suffered from the obstetrical bleeding were transfused with 200 parts of the re-melting frozen platelets, and then the peripheral blood platelet count, platelet increasing index(CCI), bleeding time and blood clot retraction rate etc. were observed for determining the clinical efficiency of the frozen platelets.</p><p><b>RESULTS</b>The floccule in the re-melting frozen platelets from the donators with (175-250)×10(9)/L platelets were decreased significantly(P<0.01). The quality of frozen platelets was influenced by the following factors, such as injection of DMSO at a too fast and heterogeneous rate, blood bags stored in a multilamminar space, and re-melting in a water-bath of small capacity etc. The routine storage for 0 and 3 days did not influence the quality of the frozen platelets. The recovery rate of one year-freezing platelets all was higher than 80%. The effects of the frozen platelets transfused into the patients with obstetrical bleeding displayed good haemostatic results, and the blood transfusion reaction did not occur. However, the frozen platelets immediately were exhausted and displayed their function, but the counting after 48 hrs could not display a good effect of raising platelet number.</p><p><b>CONCLUSIONS</b>The peripheral platelet count before platelet pheresis, the injection rate and evenness of the protective agent, the number of stratum for blood bags and the capacity of re-melting water-bath etc. all are the key factors influencing the quality of the frozen platelets. The frozen platelets prepared in this study shows a good efficacy of clinical application.</p>

Cryopreservation of platelets after storage at normal temperature for 3 days and its clinical practice / 中国实验血液学杂志

This study was purposed to investigate the feasibility of cryopreservation platelets under -80 degrees C after stored for 3 days at normal temperature and its clinical use. The platelet count, aggregation functions, adhesive ability, hypotonic shock reaction and CD62p expression of platelets preserved at normal temperature, cryopreserved on same day of collection and after storage for 3 days were detected, and possibility of using platelets cryopreserved after storage for 3 days in clinic was evaluated by comparison of contactable clinical cases. The results indicated that no significant differences in platelet count, hypotonic shock reaction and adhesive ability were found within 3 days of storage (p > 0.05); but differences in aggregation function and CD62p expression were significant (p < 0.05). As compared with platelets cryopreserved on same day of collection, the detected parameters such as platelet count, aggregation function, adhesive ability, hypotonic shock reaction, expression at storage for 3 days did not show significant differences (p > 0.015; CCI value in clinically use of them also did not show significant difference too (p > 0.05). It is concluded that the platelets after storage for 3 days can be cryopreserved, the efficiency of them in clinical use is not significant difference from platelets cryopreserved on same day of collection.